Cochlear gene therapy.
Cochlear gene therapy.
复制标题
人工耳蜗基因治疗。
DOI：
10.1097/wco.0b013e32834f038c
复制
发表时间：
2012-02
影响因子：
4.8
通讯作者：
Akil O
中科院分区：
文献类型：
--
作者：
Lustig LR;Akil O
这篇综述的目的是强调耳蜗基因治疗在过去几年中的最新进展。在过去的十年里，基因治疗已经取得了巨大的进步。从2005年的一些开创性工作开始，记录了使用病毒介导的小鼠atonal 1基因的传递进行毛细胞再生，现在正在探索基因治疗作为多种听力损失原因的可能治疗方法。耳蜗基因治疗的最新进展包括改进的基因递送方法，更好地描绘适合于此目的的病毒载体，毛细胞再生的额外改善，以及针对自身免疫性听力损失，耳毒性，螺旋神经节存活和遗传形式的听力损失的研究。如果成功的话，耳蜗基因疗法将极大地改变我们治疗各种形式的后天性和遗传性听力损失的能力。
The purpose of this review is to highlight recent advances in cochlear gene therapy over the past several years. Cochlear gene therapy has undergone tremendous advances over the past decade. Beginning with some groundbreaking work in 2005 documenting hair cell regeneration using virallymediated delivery of the mouse atonal 1 gene, gene therapy is now being explored as a possible treatment for a variety of causes of hearing loss. Recent advances in cochlear gene therapy include improved methods of gene delivery with a better delineation of viral vectors that are suitable for this purpose, additional improvements in hair cell regeneration, and directed research towards autoimmune hearing loss, ototoxicity, spiral ganglion survival, and genetic forms of hearing loss. If successful, cochlear gene therapy will dramatically alter our ability to treat a variety of forms of acquired and genetic hearing loss.